The rate of secondary involvement of the central nervous system (CNS) in lymphoma varies widely by histology but is
|
|
- Christian Bryan
- 5 years ago
- Views:
Transcription
1 Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma Jeremy S. Abramson, MD 1,2 ; Matthew Hellmann, MD 1,2 ; Jeffrey A. Barnes, MD, PhD 1,2 ; Peter Hammerman, MD, PhD 1,2 ; Christiana Toomey, BA 1 ; Tak Takvorian, MD 1,2 ; Alona Muzikansky, MA 3 ; and Ephraim P. Hochberg, MD 1,2 BACKGROUND: The outcome of patients with systemic diffuse large B-cell lymphoma (DLBCL) had improved over the past decade with the addition of monoclonal antibody therapy. Unfortunately, approximately 5% of these patients still developed a secondary central nervous system (CNS) recurrence followed invariably by rapid death. This rate is substantially increased in patients with certain high-risk features. Although prophylaxis against CNS recurrence with either intrathecal or intravenous methotrexate is commonly used for such patients, to the authors knowledge, there is no standard of care. Retrospectively evaluated was the role of high-dose systemic methotrexate combined with standard cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (R-CHOP) chemotherapy to decrease CNS recurrence in high-risk patients. METHODS: A total of 65 patients with DLBCL and CNS risk factors were identified at the study institution between 2000 and 2008 who received intravenous methotrexate as CNS prophylaxis concurrent with standard systemic therapy with curative intent. CNS recurrence rate, progression-free survival, and overall survival were calculated. RESULTS: Patients received a median of 3 cycles of methotrexate at a dose of 3.5 gm/m 2 with leucovorin rescue. The complete response rate was 86%, with 6% partial responses. At a median follow-up of 33 months, there were only 2 CNS recurrences (3%) in this high-risk population. The 3-year progression-free and overall survival rates were 76% and 78%, respectively. Complications associated with methotrexate therapy included transient renal dysfunction in 7 patients and a delay in systemic chemotherapy in 8 patients. CONCLUSIONS: Intravenous methotrexate can be safely administered concurrently with R-CHOP and is associated with a low risk of CNS recurrence in high-risk patients. Cancer 2010;116: VC 2010 American Cancer Society. KEYWORDS: diffuse large B-cell lymphoma, central nervous system lymphoma, central nervous system prophylaxis, methotrexate. The rate of secondary involvement of the central nervous system (CNS) in lymphoma varies widely by histology but is nearly always devastating. CNS dissemination in Burkitt and lymphoblastic lymphomas approaches 30%, 1 necessitating the routine incorporation of intravenous and intrathecal (IT) prophylaxis against secondary CNS disease in the treatment programs for these histologies. The risk of CNS involvement and subsequent need for prophylaxis are less well described for diffuse large B-cell lymphoma (DLBCL), the most common non-hodgkin lymphoma, and there is no standard of care. DLBCL carries a rate of secondary CNS involvement of approximately 3% to 5%, but the rate is considerably higher in patients with certain high-risk clinical features present at the time of diagnosis. 1-3 These risk factors include the involvement of specific extranodal sites (bone marrow, testes, and paranasal sinuses, as well as perhaps the kidneys, adrenal glands, liver, and breast). 1,4-10 Multivariate risk models have further identified the combination of an elevated lactate Corresponding author: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114; Fax: (617) ; jabramson@partners.org 1 Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; 2 Department of Medicine, Harvard Medical School, Boston, Massachusetts; 3 Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts DOI: /cncr.25278, Received: September 21, 2009; Revised: December 10, 2009; Accepted: December 29, 2009, Published online June 8, 2010 in Wiley Online Library (wileyonlinelibrary.com) Cancer September 15,
2 dehydrogenase (LDH) and involvement of 2 extranodal sites as conferring a risk of CNS recurrence as high as 34%. 1,11 A large Norwegian retrospective analysis identified 5 independent risk factors for CNS recurrence: elevated LDH, age >60 years, involvement of >1 extranodal site, retroperitoneal lymph node involvement, and hypoalbuminemia. 3 When >3 of these risk factors were present at diagnosis, the risk of CNS recurrence exceeded 25%. The clinical outcome of CNS recurrence in patients with DLBCL is poor, with rapid morbidity and death within 2 to 5 months. 1,3,5 Identification of DLBCL patients at high risk for subsequent CNS recurrence provides the opportunity to offer prophylactic therapy at the time of diagnosis. Highdose methotrexate is uniformly included in regimens for the therapy for Burkitt lymphoma and lymphoblastic lymphoma and is the most active single agent in the therapy of primary CNS DLBCL. Despite these implications, to our knowledge there is no clear standard for CNS prophylaxis in high-risk DLBCL patients. IT methotrexate has been most commonly used historically, 12 but evidence of benefit has been equivocal, with no protective benefit observed in 2 large randomized controlled treatment trials of DLBCL. 2,11,13-15 By contrast, the combination of systemic and IT methotrexate has demonstrated effective reduction in CNS recurrence in DLBCL, 16 suggesting that intravenous methotrexate may be primarily responsible for the risk reduction; however, the protective benefit of intravenous high-dose methotrexate without concurrent IT chemotherapy has never been formally evaluated. In the current study, we present what to the best of our knowledge is the first report of high-dose systemic methotrexate combined with standard chemoimmunotherapy to decrease CNS recurrence in high-risk DLBCL patients. MATERIALS AND METHODS We queried our Institutional Review Board-approved clinicopathologic database, derived from comprehensive tumor registry data at the Massachusetts General Hospital, for all patients aged 18 years who were diagnosed with DLBCL between 2000 and A total of 1283 patients with DLBCL were identified in the database, 65 of whom (5%) met inclusion criteria and are included in the analysis. Patients were selected for inclusion if they were treated with curative intent with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), with or without rituximab (R-CHOP), plus at least 1 infusion of systemic intravenous methotrexate at a dose of 3.5 g/m 2 for CNS prophylaxis. CHOP and R-CHOP were administered by standard protocol on a 21-day cycle. 17 Patients were not included if they presented with primary DLBCL of the CNS, or concurrent CNS and systemic involvement by DLBCL at diagnosis. CNS involvement was determined by neuroimaging or cerebrospinal fluid (CSF) examination in symptomatic patients at the discretion of the treating physician. Patients were not included if their pathology was consistent with Burkitt lymphoma or highgrade B-cell lymphoma with intermediate features between DLBCL and Burkitt lymphoma. All patients were considered high risk for CNS recurrence based on published risk models, including involvement of >2 extranodal sites plus an elevated LDH 1,18 ; Hollender 5- point criteria 3 ; or high-risk locations including bone marrow, paranasal sinuses, testes, epidural disease, liver, adrenal, renal, or orbit. 1,5,6 Discordant bone marrow involvement by a low-grade lymphoma was not considered an indication for CNS prophylaxis. Progression-free and overall survival rates with 95% confidence intervals (95% CI) were calculated from date of diagnosis to disease progression or death, or death, respectively, and were plotted by the method of Kaplan and Meier. RESULTS Sixty-five patients met inclusion criteria and were included in the analysis. Patient characteristics are summarized in Table 1. The median age at diagnosis was 60 years (range, years), and 63% of patients were male. The majority of patients had Ann Arbor stage IV disease (73%). Using the revised International Prognostic Index (IPI) score, 44 (68%) patients were high risk (score of 3-5), predicting for a 4-year overall survival rate of 55%. 19 One patient had human immunodeficiency virus infection. LDH was elevated in 73% of patients, and 64 of 65 patients had extranodal involvement of their DLBCL. Lumbar punctures (LPs) were performed at diagnosis in 19 patients, all of which were negative by cell counts. Seventeen LPs underwent cytologic examination and 14 underwent flow cytometry, none of which were positive for malignant cells, although 2 flow cytometries were believed to be equivocal due to paucity of cells, and had negative accompanying cytology and cell count and are included in the analysis. These LPs were performed at the discretion of the treating physician. Cytogenetic information was available on 27 patients, 6 of whom had a BCL2 rearrangement, 3 patients had a c-myc rearrangement, and 5 had complex karyotypes. Two patients had 4284 Cancer September 15, 2010
3 IV MTX for CNS Prophylaxis in DLBCL/Abramson et al Table 1. Patient Characteristics Characteristic No. Table 2. Summary of CNS Risk Factors CNS Risk Factor No. % Total no. of patients 65 Median age (range), y 60 (25-79) Male:female ratio 41:24 Histology DLBCL 61 PMBCL 4 Stage I 11 Stage II 2 Stage III 3 Stage IV 48 Elevated LDH 48 Extranodal sites >1 39 Any extranodal disease 64 Median no. of extranodal sites 2 (range 0-5) Bulky disease (>7cm) 13 Chemotherapy R-CHOP-M 63 CHOP-M 2 Median no. of CHOP cycles (range) 6 (3-8) Median no. of HD methotrexate cycles (range) 3 (1-8) Consolidative radiotherapy 16 Diagnostic LP (all negative) 19 IT at diagnostic LP 4 ECOG Performance status IPI 0, 1 8 IPI 2 13 IPI 3, 4, 5 44 DLBCL indicates diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; LDH, lactate dehydrogenase; R-CHOP-M, cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab plus at least 1 infusion of systemic intravenous methotrexate; HD, high-dose; LP, lumbar puncture; IT, intrathecal; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index. concurrent rearrangements of c-myc and BCL2. Ki-67 staining was performed on 46 cases at diagnosis, among which the median Ki-67 proliferation index was 78% (range, %). Fourteen cases (30%) had a proliferation index of >90%. Sixty-three patients received R-CHOP, and 2 patients received CHOP without rituximab. CHOP/R- >1 extranodal site >1 extranodal site and elevated LDH Hollender score of High-risk sites Bone marrow Testis 5 8 Paranasal sinus 6 9 Orbit 9 14 Breast 1 2 Renal/adrenal 9 14 Liver 8 12 Epidural disease CNS indicates central nervous system; LDH, lactate dehydrogenase. Table 3. Outcome 3-Year Outcome No. % ORR CRR OS (95% CI) (64-88) PFS (95% CI) (62-86) CNS recurrence 2 3 ORR indicates overall response rate; CRR, complete response rate; OS, overall survival; 95% CI, 95% confidence interval; PFS, progression-free survival; CNS, central nervous system. CHOP was given for a median of 6 cycles, with 44 patients receiving 6 cycles, 12 receiving 7 to 8 cycles, and 9 receiving 3 to 4 cycles. Methotrexate was administered to all patients at a dose of 3.5 g/m 2 intravenously for a median of 3 cycles (range, 1-8 cycles). Methotrexate was most commonly administered on Day 15 of alternating cycles of R-CHOP (ie, with Cycles 2, 4, and 6), as an inpatient with leucovorin rescue. Four patients received a single dose of IT methotrexate at the time of diagnostic LP. Sixteen patients received consolidative involved field radiotherapy. The indications for CNS prophylactic therapy are summarized in Table 2. Most prophylactic therapy was given to patients with multiple extranodal sites plus an elevated LDH (46%), followed by involvement of bone marrow (22%); epidural disease (22%); a Hollender score of 4 or 5 (17%); and involvement of the kidney or adrenal gland (14%), orbit (14%), liver (12%), paranasal sinuses (9%), testes (8%), and breast (2%). Patients frequently had >1 of the above risk factors present at diagnosis. The median follow-up is 33 months. Outcome is summarized in Table 3. The overall systemic response rate was 92%, with 56 patients (86%) achieving a complete Cancer September 15,
4 survival rate was 78% (95% CI, 64-88%) (Fig. 1). Among all patients with recurrent disease, the median Ki-67 proliferation index of diagnostic biopsy specimens was 70% (range, 50-90%). Among 11 patients with recurrent systemic disease, the median follow-up is 2 years with 4 patients remaining alive at last follow-up. CNS recurrence occurred in only 2 patients (at 4 months and 9 months, respectively from diagnosis), yielding a CNS recurrence rate of 3% in this high-risk population. Both patients died of their CNS recurrence at 32 days and 127 days from recurrence, respectively. One patient had received IT methotrexate at the time of initial diagnostic LP, which was equivocal by flow cytometry and negative by cytology and cell count. The other patient did not have an LP at diagnosis. Both patients received R- CHOP. One patient developed disease recurrence during treatment exclusively in the leptomeninges after receiving 3 cycles of R-CHOP and 1 infusion of systemic methotrexate. The other patient completed 6 cycles of R-CHOP and 5 infusions of systemic methotrexate, and presented 48 days after completing chemotherapy with CNS recurrence in the brain parenchyma and leptomeninges, as well as systemic disease recurrence. The indication for CNS prophylaxis was bone marrow involvement by DLBCL in both patients. LDH was markedly elevated in both patients at diagnosis (2764 U/L and 798 U/L; normal range for our laboratory, U/L). Ki-67 staining at initial diagnosis was available in only one of these patients and was 70%. Neither patient had a detectable c-myc rearrangement. Figure 1. (A) The 3-year progression-free survival (PFS) rate for the entire cohort was 76% (95% confidence interval [95% CI], 62-86%). (B) The 3-year overall survival rate for the entire cohort was 78% (95% CI, 64-88%). response, 4 patients (6%) achieving a partial response, and 5 (7%) developing disease progression during induction therapy. There were 11 systemic recurrences outside of the CNS at a median of 14 months (range, 3-51 months) from diagnosis. The 3-year progression-free survival rate was 76% (95% CI, 62-86%), and the overall Toxicity The median creatinine at baseline was 0.9 mg/dl (range, mg/dl). The median maximal creatinine within 2 weeks of the first methotrexate infusion was 1.1 mg/dl (range, mg/dl). Twenty-six patients had renal toxicity, defined as an increase in serum creatinine above the upper limit of normal; 10 of these patients (38%) were aged 60 years and 16 patients (62%) were aged >60 years. After the first methotrexate infusion, 7 patients had an elevation in their creatinine to 2.0 mg/dl, 3 of whom did not receive further methotrexate infusions but subsequently had complete recovery of renal function. One of these cases of renal failure occurred in the setting of recent intravenous contrast administration. Sixty-one patients received a second infusion of high-dose methotrexate, at which time the baseline creatinine was again 0.9 mg/dl (range, mg/dl). Only 2 patients experienced elevations in their creatinine 2 mg/ 4286 Cancer September 15, 2010
5 IV MTX for CNS Prophylaxis in DLBCL/Abramson et al dl, both of whom had also had developed creatinine >2 mg/dl after the first methotrexate infusion. Among patients without renal dysfunction after Cycle 1, there was no renal dysfunction with Cycle 2. Fifty-eight patients received a third infusion of highdose methotrexate, with a median baseline creatinine of 0.9 mg/dl (range, mg/dl). Two patients experienced creatinine elevations 2 mg/dl, and received no further methotrexate. One patient developed a creatinine of 6 and required temporary hemodialysis with subsequent recovery to dialysis independence. No other patient in this series required renal replacement therapy. Nineteen patients received a fourth infusion of high-dose methotrexate, 12 a fifth cycle, 6 a sixth cycle, and 1 a seventh and eighth cycle. There were no episodes of acute renal failure during methotrexate cycles 4 to 8. For the entire cohort, the median end of treatment creatinine was 1.1 mg/dl (range, mg/dl), with only 2 patients having creatinine 2 mg/dl. Nine patients (14%) had planned additional methotrexate treatments aborted due to nephrotoxicity. Eight patients (12%) experienced a delay in R-CHOP because of methotrexate toxicity. Six patients had delay of 1 cycle, and 1 patient had 2 cycles delayed. Of the 8 delayed R- CHOP cycles, 3 were by 1 week, 3 were by 2 weeks, and 2 were by 3 weeks. Reason for dose delay was renal toxicity in 4 cycles, mucositis in 2 cycles, cytopenias in 2 cycles, and both cytopenias and renal dysfunction in 1 cycle. One patient died during treatment of chemotherapy-related complications, including nephrotoxicity, mucositis, pneumonia, and pancytopenia. DISCUSSION The results of the current study demonstrate that incorporation of intravenous systemic methotrexate at a dose of 3.5g/m 2 into the standard R-CHOP treatment regimen is associated with decreased CNS recurrence risk compared with the published outcome in high-risk patients who did not receive CNS prophylaxis. Our 3-year progression-free survival rate approaching 80% is particularly encouraging in a cohort of patients with a preponderance of high-risk features for systemic disease recurrence, including highrisk IPI scores and high Ki-67 proliferation fractions. Previous series demonstrate a CNS recurrence risk of 2% to 8% in patients with DLBCL in general, 1-3,5,11 but none of these series were limited to high-risk patients, among whom the incidence of CNS recurrence is known to be significantly higher. Specific extranodal sites are highly associated with an elevated risk of CNS recurrence, perhaps due to differential expression of integrin or chemokine receptor profiles that allow colonization of these sites. 20 Involvement of the bone marrow, testes, and paranasal sinuses as well as the kidneys, adrenal glands, liver, bladder, breasts, mediastinum, bone, epidural space, and peripheral blood have all been associated with an increased risk of CNS recurrence. 1,4-10,21 In addition, univariate risk factor analysis of patients who develop CNS recurrence also has identified LDH elevation, the presence of extranodal sites of disease, age, and B symptoms as conferring an increased risk of CNS recurrence. 1,3,18 On multivariate analysis, the presence of an elevated LDH in concert with the involvement of multiple extranodal sites by DLBCL appears to be the most strongly predictive clinical algorithm, predicting a CNS recurrence risk of 17% to 34%. 1,5,11 In our series, 30 patients met these criteria, none of whom experienced a CNS recurrence. Both CNS recurrences in this series occurred in patients with bone marrow involvement by their DLBCL, which yields a 9% rate of CNS recurrence among the 22 total patients with bone marrow involvement at baseline. Involvement of the bone marrow has been associated with a nearly 20% risk of CNS recurrence, 1 although this has not been uniformly observed across published series. No CNS recurrences were observed in patients with risk due to other identified highrisk locations including testes, paranasal sinuses, kidneys, orbit, breast, or epidural space, but the small subset of patients in each of these groups prevents drawing conclusions regarding the efficacy of systemic methotrexate in preventing recurrence due to a specific site of high-risk disease. It is not routine practice at our institution to perform LPs at the time of DLBCL diagnosis in the absence of neurologic signs or symptoms; however, 19 of the 65 patients had an LP performed before the initiation of systemic therapy at the discretion of the treating physician. Sixteen (84%) of these LPs were sent for flow cytometry, which has been shown to be the more sensitive than cell counts or cytology in detecting occult CNS involvement of the CSF. 22 Two of the 16 samples sent for flow cytometry were equivocal for the presence of clonal B cells due to a paucity of cells for analysis; in both of these cases, the cytology was negative. One of the patients with equivocal flow cytometry results at diagnosis subsequently developed a CNS recurrence. The majority of CNS recurrences in patients with DLBCL occur during or shortly after the completion of Cancer September 15,
6 induction chemotherapy. 3,5 The timing of these recurrences suggests that occult microscopic disease may already be present at the time of diagnosis. Before the addition of rituximab to chemotherapy regimens, these recurrences preferentially involved the leptomeninges in approximately 70% of cases. 1,3,23 However, DLBCL of the testes has consistently demonstrated a unique natural history with late recurrences and a predilection for the brain parenchyma. 2,7,8 The prominent leptomeningeal pattern of DLBCL recurrence led to the adoption of IT prophylactic therapy with methotrexate, with some retrospective analyses suggesting benefit, 13,15,18 and others no benefit. 2,11,14 Two prospective controlled trials have randomized DLBCL patients to therapeutic regimens either containing or not containing prophylactic CNS therapy with IT methotrexate. Southwest Oncology Group 8516 (SWOG) was a 4-arm randomized trial of front-line therapy in DLBCL that included 2 arms with CNS prophylaxis for patients with bone marrow involvement (prednisone, procarbazine, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, and methotrexate [ProMACE-CytaBOM] and methotrexate, doxorubicin, cyclophosphamide, and vincristine [MACOP-B]), and 2 arms without CNS prophylaxis (CHOP and methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone [m- BACOD]). Patients treated with ProMACE-CytaBOM received consolidative whole-brain radiotherapy to 24 gray (Gy) after chemotherapy if bone marrow was involved at diagnosis. Patients on the MACOP-B arm with a positive bone marrow at diagnosis received prophylaxis with IT methotrexate and cytarabine twice weekly for 6 doses. Both arms also included intravenous methotrexate, but at significantly lower doses than are required to achieve significant CNS penetration. The overall rate of CNS recurrence in this trial was 2.8%, with no benefit noted in patients treated with prophylactic IT therapy or whole-brain irradiation. 2 The RICOVER-60 trial randomized patients to R-CHOP at 14-day or 21-day intervals and included IT prophylaxis with methotrexate for all high-risk patients (22%) defined by disease involvement of the bone marrow, paranasal sinuses, orbits, oral cavity, tongue, or salivary glands. 11 Of the total 1217 patients, 58 (4.8%) experienced a CNS recurrence; however, this rate rose to 34% in those patients with an elevated LDH and at least 2 extranodal sites of involvement. The incidence of CNS recurrence was not affected by the incorporation of IT therapy. The most compelling evidence for effective prophylaxis against CNS recurrence comes from the GELA LNH 93-5 trial, which randomized patients with aggressive lymphomas and an age-adjusted IPI score of 1 to either CHOP-21 or the intensive ACVBP regimen. 16 The majority of patients (80%) had doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (DLBCL). CHOP patients received no CNS prophylaxis, whereas all ACVBP patients received 4 doses of IT methotrexate (15 mg), and 2 infusions of intravenous methotrexate at a dose of 3000 mg/m 2 with leucovorin rescue. The primary outcome of the trial demonstrated an improved overall survival for ACVBP-treated patients complicated by a higher treatment-related death rate. Notably, ACVBP-treated patients experienced significantly fewer CNS recurrences than CHOP patients (2.7% vs 8%). Although patients in this trial received both IT and intravenous prophylaxis, the preponderance of evidence, in conjunction with the SWOG and RIC- OVER-60 data, suggests that the intravenous methotrexate provided the improvement in efficacy. Our data validate the hypothesis that effective CNS prophylaxis can be provided with intravenous methotrexate alone in a high-risk cohort of DLBCL patients. High-dose methotrexate overcomes multiple potential liabilities of IT therapy, including uneven distribution within the neuroaxis, and failure to significantly penetrate the brain parenchyma. Lumbar administration of IT methotrexate results in marked differences in peak levels throughout the subarachnoid space, and subtherapeutic levels are common, resulting largely from differences in bulk CSF movement, choroidal uptake, and drug clearance. 24 Intraventricular administration by means of an implantable Ommaya reservoir improves drug distribution around the brain, but lumbar concentrations remain lower. 24,25 In contrast, intravenous administration of methotrexate produces therapeutic drug levels that are evenly distributed throughout the entire subarachnoid space. 24 All but 2 patients in our analysis received rituximabcontaining therapy. The addition of rituximab to standard CHOP-21 appeared to have no influence on CNS recurrences in the landmark GELA trial of R-CHOP versus CHOP, with an overall 5% risk of CNS recurrence reported among elderly patients with DLBCL, regardless of treatment arm. 23 However, when the RICOVER-60 trial compared R-CHOP with CHOP in a dose-dense manner, there were modestly fewer recurrences in the rituximab-treated patients noted on univariate analysis 4288 Cancer September 15, 2010
7 IV MTX for CNS Prophylaxis in DLBCL/Abramson et al (6.9% vs 4.1%), although this was not significant on multivariate analysis. A notable observation in both the GELA and RICOVER-60 trials was that CNS recurrences in R- CHOP-treated patients were predominantly parenchymal, not leptomeningeal, as had been reported before the introduction of rituximab. This intriguing observation raises the question of whether small amounts of rituximab are able to penetrate and protect the leptomeningeal compartment and not the parenchyma. The increase in parenchymal recurrences in modern series further supports the role of intravenous prophylaxis against CNS recurrence in combination with rituximab-containing combination chemotherapy regimens. We also demonstrate that high-dose methotrexate with concurrent R-CHOP can be administered safely, even to elderly patients. Although renal dysfunction may occur, it is uncommon and almost always self-limited. Patients with renal impairment at baseline are not candidates for this approach, nor are patients with significant effusions or ascites, which serve as a reservoir for methotrexate, resulting in extended toxicity. Careful attention to adequate hydration, alkalinization of the urine, and leucovorin rescue is critical to safe administration of intravenous methotrexate, and methotrexate levels and renal function must be closely followed after drug administration. This study is limited by its retrospective nature, but to the best of our knowledge there are no prospective studies specifically evaluating the optimal method of preventing CNS recurrence in high-risk DLBCL patients. Patients were selected for inclusion only if they had no evidence of CNS involvement at the time of DLBCL diagnosis. The majority of patients did not have diagnostic LPs, which is consistent with standard of care when LPs are not part of routine staging in DLBCL. Patients with diagnostic LPs demonstrating CNS involvement were excluded from our analysis to focus purely on the question of prophylaxis. It is possible that our CNS recurrence rate was low, in part, due to a better job of excluding patients with occult CNS disease than previously published series due to exclusion of patients with positive flow cytometry of diagnostic CSF, thus making our data appear more favorable. It is likewise possible that some patients with occult involvement of their CSF were included in the analysis because most patients did not undergo diagnostic LP in this series. Placing our results in the context of the existing data, we suggest that systemic intravenous methotrexate at a dose of 3500 mg/m 2 followed by leucovorin rescue be adopted for CNS prophylaxis in high-risk patients, and that IT therapy be considered only for those patients who cannot tolerate systemic therapy. Further investigation is necessary to better understand the optimal dose, quantity, and timing of high-dose systemic methotrexate required to achieve effective prophylaxis against recurrent CNS disease while minimizing potential toxicities associated with this therapy and will optimally be investigated in the context of prospective clinical trials. CONFLICT OF INTEREST DISCLOSURES Dr. Hochberg has received consulting and speaking fees from Enzon pharmaceuticals. REFERENCES 1. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91: Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-hodgkin s lymphoma: a 20-year followup analysis of SWOG 8516 the Southwest Oncology Group. J Clin Oncol. 2009;27: Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-hodgkin s lymphoma: a risk model. Ann Oncol. 2002;13: Bunn PA Jr, Schein PS, Banks PM, DeVita VT Jr. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood. 1976;47: Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18: Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-hodgkin s lymphoma: the risk factors. Hematol Oncol. 1990;8: Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88: Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. JClinOncol.2003;21: Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk Lymphoma. 2003;44: Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-hodgkin lymphoma of the breast: the Mayo Clinic Experience. J Surg Oncol. 2002;80:19-25; discussion Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) Cancer September 15,
8 with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non- Hodgkin lymphoma study group (DSHNHL). Blood. 2009;113: Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131: Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer. 2002;95: Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-hodgkin s lymphoma. Leuk Lymphoma. 2002;43: Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18: Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-hodgkin lymphoma. Blood. 2003;102: Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med. 2002;346: Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-hodgkin s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d Etudes des Lymphomes de l Adulte. Ann Oncol. 2000;11: Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109: Fujii A, Ohshima K, Hamasaki M, et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol. 2004;24: Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17: Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-hodgkin s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27: Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-b-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15: Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293: Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000;45: Cancer September 15, 2010
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationEffects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B cell lymphoma
MOLECULAR AND CLINICAL ONCOLOGY 3: 747-752, 2015 Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B cell lymphoma MAN FAI LAW 1,2*, HAY NUN
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationPrevention of CNS relapse in diffuse large B-cell lymphoma
Prevention of C relapse in diffuse large B-cell lymphoma Robert Kridel, Pierre-Yves Dietrich C relapse occurs in about 5% of patients during the course of diffuse large B-cell lymphoma and entails a dismal
More informationIncidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-b-cell lymphoma: influence of rituximab
Original article Annals of Oncology 15: 129 133, 2004 DOI: 10.1093/annonc/mdh013 Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-b-cell lymphoma:
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationCentral nervous system relapse of diffuse large B-cell lymphoma in the. rituximab era: Results of the UK NCRI R-CHOP-14 versus 21 trial
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: Results of the UK NCRI R-CHOP-14 versus 21 trial Central nervous system relapse of diffuse large B-cell lymphoma in
More informationCNS prophylaxis in aggressive non-hodgkin s lymphoma
232 CNS prophylaxis in aggressive non-hodgkin s lymphoma C. Meert, MD, D. Dierickx, MD, PhD, V. Vergote, MD, G. Verhoef, MD, PhD, A. Janssens, MD, PhD SUMMARY Although it doesn t occur frequently, central
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
More informationPrimary testicular DLBCL 171. Table 1. Patient characteristics, treatment modalities, and outcomes. a) Elevated LDH: >250 IU/L.
BLOOD RESEARCH VOLUME 49 ㆍ NUMBER 3 September 2014 ORIGINAL ARTICLE Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationDiffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults: A High-Grade Lymphoma Responsive to ProMACE-Based Combination Chemotherapy
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults: A High-Grade Lymphoma Responsive to ProMACE-Based Combination Chemotherapy By Dan L. Longo, Patricia L. Duffey, Elaine S. Jaffe, Mark Raffeld,
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationTraitement des lymphomes diffus à grandes cellules B
Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationDiffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse
Published Ahead of Print on April 12, 2011, as doi:10.3324/haematol.2011.041277. Copyright 2011 Ferrata Storti Foundation. Early Release Paper Diffuse large B-cell lymphoma with involvement of the kidney:
More informationCHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA
Aria Oncologicu Vol., No. 8, pp. 95-99, 1994 CHOP CHEMOTHERAPY OF INTERMEDIATE AND HIGH-GRADE NON-HODGKIN S LYMPHOMA MARTA LLANOS, JOSEP TABERNERO, JOAN BRUNET, MARGARITAMENEDO, CINTA PALLARES, LUIS DE
More information113 patients was assembled from 13 investigators;
CLINICAL TRIALS AND OBSERVATIONS Brain parenchyma involvement as isolated central nervous system relapse of systemic non-hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationDurable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit DLBCL treated with lenalidomide monotherapy Running head: Durable remission with lenalidomide in CNS relapse
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationINTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES. Samo Rožman Institute of Oncology Ljubljana Slovenia
INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES Samo Rožman Institute of Oncology Ljubljana Slovenia AGENDA 1. INTRATHECAL APPLICATION 2. MONOCLONAL ANTIBODIES 3. MALIGNANT CARCINOMATOSIS 4. INTRATHECAL
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationImportance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma
Review Article J Clin Exp Hematopathol Vol. 51, No. 1, May 2011 Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma Hiroki Yamaguchi, Tsuneaki Hirakawa, and Koiti Inokuchi
More informationDOI: /annonc/mds621. Published: Link to publication
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma
More informationAPPROXIMATELY 50% of patients with non-
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin s Lymphoma By J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez,
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationR-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study
Hematological Oncology Hematol Oncol 2008; 26: 27 32 Published online 17 September 2007 in Wiley InterScience (www.interscience.wiley.com).829 Research Article R-CHOP-14 in patients with diffuse large
More informationJournal of American Science 2016;12(6)
Role of reduced dose CHOP with Rituximab plus involved field radiotherapy in treatment of early stage diffuse large B cell lymphoma in elderly patients Lobna A. Abdelaziz 1, Reham A. Salem 1, Nabila Hefzi
More informationExtranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence
More informationBrief Communication Diagnostic Hematology
Brief Communication Diagnostic Hematology Ann Lab Med 2019;39:200-204 https://doi.org/10.3343/alm.2019.39.2.200 ISSN 2234-3806 eissn 2234-3814 Cluster Containing More Than 20 CD3-Positive Cells in Bone
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx128 Published online 7 April 2017
Annals of Oncology 28: 54 546, 27 doi:.93/annonc/mdx28 Published online 7 April 27 ORIGINAL ARTICLE Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationNICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52
Non-Hodgkin s lymphoma: diagnosis and management NICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationRole of prophylactic radiotherapy in Chinese patients with primary testicular diffuse large B-cell lymphoma: a single retrospective study
JBUON 2019; 24(2): 754-762 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Role of prophylactic radiotherapy in Chinese patients with primary testicular
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationLearn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1
Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1 Expression of B-cell surface antigens drives several non-hodgkin s lymphomas (NHLs)
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationChristian Rübe, and Michael Pfreundschuh, J Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 11 APRIL 1 14 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma Gerhard Held, Niels Murawski,
More informationNK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationPopulation based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Wästerlid, Tove; Jonsson, Björn; Hagberg, Hans; Jerkeman, Mats Published in: Leukemia
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationCNS disease in hematologic malignancies S3 leukemia are available, the standard method is light microscopic examination of cytospin preparations of ce
Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications Ching-Hon Pui a and Eckhard Thiel b Acute lymphoblastic leukemia (ALL) 5-year survival rates
More informationEffects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients
[Chinese Journal of Cancer 27:10, 363-367; October 2008]; 2008 Sun Yat-Sen University Cancer Center Clinical Research Paper Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationPrognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
More informationMOLECULAR AND CLINICAL ONCOLOGY 1: , 2013
MOLECULAR AND CLINICAL ONCOLOGY 1: 911-917, 2013 Significance of clinical factors as prognostic indicators for patients with peripheral T cell non Hodgkin lymphoma: A retrospective analysis of 252 cases
More informationORIGINAL ARTICLE INTRODUCTION. Yun Hwa Jung, In Sook Woo, and Chi Wha Han
ORIGINAL ARTICLE Korean J Intern Med 2015;30:684-693 Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature
More informationDiffuse large B-cell lymphomas. G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013
Diffuse large B-cell lymphomas G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013 Case A 72-year-old previously healthy man presented with acute abdominal pain and a 15 kg weight loss. Positron
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationIntroduction ORIGINAL RESEARCH. Yoon Ah Cho 1, Woo Ick Yang 1, Jae-Woo Song 2, Yoo Hong Min 3 & Sun Och Yoon 1. Open Access.
Cancer Medicine ORIGINAL RESEARCH Open Access The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B- cell aggregates in the bone marrow of patients
More informationKEYWORDS: Aggressive lymphoma, High-dose therapy, Autologous stem cell transplant, Immunochemotherapy INTRODUCTION
Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study Marie-Sarah Dilhuydy, 1 Thierry
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationOriginal Article. Introduction
Original Article Radiat Oncol J 217;35(4):317-324 https://doi.org/1.3857/roj.217.451 pissn 2234-19 eissn 2234-3156 Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationBurkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS
Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationRole of high-dose therapy in diffuse large B-cell lymphoma
Role of high-dose therapy in diffuse large B-cell lymphoma Thomas Cerny a and Daniel Betticher b ' Department Internal Medicine, Head of Oncology / Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationDefinition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:
INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum
More informationORIGINAL ARTICLE. Keywords Relapse/refractory. DLBCL. Immunochemotherapy. Introduction
Ann Hematol (2015) 94:803 812 DOI 10.1007/s00277-014-2271-1 ORIGINAL ARTICLE Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy
More informationBurkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma.
INDICATION Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationThe role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas
Regular Article From www.bloodjournal.org by guest on April 30, 2018. For personal use only. CLINICAL TRIALS AND OBSERVATIONS The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationTreatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
BLOOD RESEARCH VOLUME 51 ㆍ NUMBER 3 September 2016 ORIGINAL ARTICLE Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas Ji Young Lee 1, Sang Min Lee 1,
More informationADDITION OF RITUXIMAB SIGNIFICANTLY IMPROVES OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA A SINGLE-CENTER, RETROSPECTIVE STUDY
ORIGINAL ARTICLE ADDITION OF RITUXIMAB SIGNIFICANTLY IMPROVES OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA A SINGLE-CENTER, RETROSPECTIVE STUDY David Belada 1, Lukáš Smolej 1, Monika Hrudková
More information